May 2013, Vol 2, No 3

← Back to Issue

Personalized Medicine in Oncology: Providing Insights to Optimally Utilize Personalized Medicine Concepts

Greg Kalemkerian, MD

Uncategorized

Dear Colleague,

I want to welcome you to this issue of Personalized Medicine in Oncology (PMO) with a few facts concerning personalized medicine (PM):

  • 79% of late-stage oncology pipeline are targeted therapies
  • Molecular profiling is driving many new targeted cancer therapeutics, with over 500 compounds coming soon, and 140 targets in development
  • Companion diagnostics are playing an increasingly greater role in cancer product launches


Taken alone, any of these developments would call for intensified efforts to educate practicing oncologists in PM systems and resources. Taken together, they are a clarion call for extraordinary measures to ensure that this happens.

PM is a medical art form requiring awareness of key diagnostic and therapeutic resources. The demand for excellence by patients and caregivers is matched by the demand for value by payers and purchasers. All of these parties recognize cancer as the deadly enemy and will go to great lengths to obtain patient-
centered, value-based care.

Enter PMO. We bring oncologists the insights into the key developments in PM needed to raise their clinical skills and stay competitive through the expert use of the breakthrough treatments and diagnostics. The greatest clinical armamentarium is meaningless without knowledge of its proper deployment…and that is what PMO brings to oncologists in every issue. Our balanced reviews and editorials give today’s oncologists the insight they need to optimally utilize the products that bring value to the patient-centered cancer care model that is taking shape before our eyes.

Sincerely,

Greg Kalemkerian, MD
University of Michigan
PMO Board Member

Uncategorized - May 23, 2013

NCCN Updates Its Clinical Practice Guidelines

Updates to the Clinical Practice Guidelines of the National Comprehensive Cancer Network (NCCN) were presented at the NCCN 18th Annual Conference held in Hollywood, FL, March 13-17, 2013. For most tumor sites, the updates were few and minor, but the NCCN did introduce inaugural guidelines for survivorship. New Guidelines for [ Read More ]

Uncategorized - June 21, 2013

Crizotinib and Colorectal Cancer – A Couple to Be Tested?

Dr Stintzing is currently a postdoctoral fellow of the German Cancer Aid at the University of Southern California/Norris Comprehensive Cancer Center. Dr Stintzing’s research focus is on predictive and prognostic factors in the treatment of metastatic colorectal cancer. Dr Lenz is the Associate Director for Clinical Research and Co-Leader of [ Read More ]